Vertex Pharmaceuticals VRTX Other Noncash Income (Expense)
Other Noncash Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's other noncash income (expense)?
- Vertex Pharmaceuticals (VRTX) reported other noncash income (expense) of $5M in Q1 2026.
- How has Vertex Pharmaceuticals's other noncash income (expense) changed year-over-year?
- Vertex Pharmaceuticals's other noncash income (expense) increased by 112.8% year-over-year, from -$39.2M to $5M.
- What is the long-term trend for Vertex Pharmaceuticals's other noncash income (expense)?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's other noncash income (expense) has grown at a 116.7% compound annual growth rate (CAGR), from -$11.8M to -$120.1M.
- What does other noncash income (expense) mean?
- This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.